A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis

Nature Cell Biology

Volumn 16, Issue 12, 2014, Pages 1238-1248

  Scheeren, Ferenc A ^a,b,f   Kuo, Angera H ^a,f   Van Weele, Linda J ^a   Cai, Shang ^a   Glykofridis, Iris ^b   Sikandar, Shaheen S ^a   Zabala, Maider ^a   Qian, Dalong ^a   Lam, Jessica S ^a   Johnston, Darius ^a   Volkmer, Jens P ^a   Sahoo, Debashis ^a,g   Van De Rijn, Matt ^a   Dirbas, Frederick M ^c   Somlo, George ^d   Kalisky, Tomer ^e,g   Rothenberg, Michael E ^a   Quake, Stephen R ^e   Clarke, Michael F ^a,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c STANFORD UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Stanford University   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; CD45 ANTIGEN; CELL ADHESION MOLECULE; DEXTRAN SULFATE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; IRAK4 PROTEIN, HUMAN; LGR5 PROTEIN, MOUSE; MYD88 PROTEIN, MOUSE; PTPRC PROTEIN, MOUSE; SMALL INTERFERING RNA; TLR2 PROTEIN, MOUSE; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST EPITHELIUM CELL; CANCER GROWTH; CARCINOGENESIS; COLITIS; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; STEM CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST; BREAST TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMICALLY INDUCED; COLON TUMOR; EPITHELIUM; GENETICS; HEK293 CELL LINE; HUMAN; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; REGENERATION; RNA INTERFERENCE; TUMOR CELL CULTURE;

MUS;

ANIMALS; ANTIGENS, CD14; ANTIGENS, CD45; ANTIGENS, NEOPLASM; BREAST; BREAST NEOPLASMS; CARCINOGENESIS; CELL ADHESION MOLECULES; COLITIS; COLONIC NEOPLASMS; DEXTRAN SULFATE; EPITHELIUM; FEMALE; HEK293 CELLS; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM TRANSPLANTATION; RECEPTORS, G-PROTEIN-COUPLED; REGENERATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TUMOR CELLS, CULTURED;

EID: 84925286089     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3058     Document Type: Article

References (65)

1. Metcalfe, C., Kljavin, N. M., Ybarra, R. &de Sauvage, F. J. Stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149-159 (2014).
2. Yu, L., Wang, L. &Chen, S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 14, 2592-2603 (2010).
3. Akira, S., Uematsu, S. &Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
4. West, X. Z. et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976 (2010).
5. Park, J. S. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917-C924 (2005).
6. Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106 (2009).
7. Yang, R-B. et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395, 284-288 (1998).
8. Lee, M. S. &Kim, Y-J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447-480 (2007).
9. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J. &Mathison, J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433 (1990).
10. Clevers, H. At the crossroads of inflammation and cancer. Cell 118, 671-674 (2004).
11. Rakoff-Nahoum, S. &Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer 9, 57-63 (2009).
12. Coussens, L. M. &Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
13. Balkwill, F. &Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
14. Rakoff-Nahoum, S. &Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124-127 (2007).
15. Takeda, K., Kaisho, T. &Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
16. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
17. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
18. Pietersen, A. M. et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr. Biol. 18, 1094-1099 (2008).
19. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
20. Uemura, N. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784-789 (2001).
21. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
22. Medzhitov, R., Preston-Hurlburt, P. &Janeway, C. A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
23. Asselin-Labat, M-L. et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor Caspase-14. Mol. Cell Biol. 31, 4609-4622 (2011).
24. Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88 (2006).
25. Stingl, J. et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006).
26. Kordon, E. C. &Smith, G. H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125, 1921-1930 (1998).
27. Schneider, D. S., Hudson, K. L., Lin, T. Y. &Anderson, K. V. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo. Genes Dev. 5, 797-807 (1991).
28. Keymeulen, A. V. et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 479, 189-193 (2011).
29. Rios, A. C., Fu, N. Y., Lindeman, G. J. &Visvader, J. E. In situ identification of bipotent stem cells in the mammary gland. Nature 506, 322-327 (2014).
30. Plaks, V. et al. Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis. Cell Rep. 3, 70-78 (2013).
31. Grivennikov, S. I. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254-258 (2012).
32. Sangiorgi, E. &Capecchi, M. R. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 40, 915-920 (2008).
33. Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255-259 (2011).
34. Montgomery, R. K. et al. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proc. Natl Acad. Sci. USA 108, 179-184 (2011).
35. Takeda, N. et al. Interconversion between intestinal stem cell populations in distinct niches. Science 334, 1420-1424 (2011).
36. Powell, A. E. et al. The Pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149, 146-158 (2012).
37. Muñoz, J. et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent C4 cell markers. EMBO J. 31, 3079-3091 (2012).
38. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007).
39. Tye, H. et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22, 466-478 (2012).
40. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. &Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004).
41. Humphreys, R. C. et al. Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development 122, 4013-4022 (1996).
42. Kitajima, S., Takuma, S. &Morimoto, M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 48, 137-143 (1999).
43. Mailleux, A. et al. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev. Cell 12, 221-234 (2007).
44. Hall, P. A., Coates, P. J., Ansari, B. &Hopwood, D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J. Cell Sci. 107, 3569-3577 (1994).
45. Bianchi, M. E. &Manfredi, A. A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220, 35-46 (2007).
46. Park, J. S. et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
47. Urbonaviciute, V. et al. Induction of inflammatory and immune responses by HMGB1- nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205, 3007-3018 (2008).
48. Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2012).
49. Reya, T., Morrison, S. J., Clarke, M. F. &Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
50. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
51. Shackleton, M., Quintana, E., Fearon, E. R. &Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009).
52. Ruark, E. et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493, 406-410 (2012).
53. Schepers, A. G. et al. Lineage tracing reveals Lgr5C stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012).
54. Dent, R. et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 115, 423-428 (2009).
55. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. &Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109, 1721-1728 (2007).
56. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502 (2006).
57. Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662-6667 (2012).
58. Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94 (2010).
59. Asselin-Labat, M-L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 9, 201-209 (2007).
60. el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186-193 (2004).
61. Rothenberg, M. E. et al. Identification of a cKit(C) colonic crypt base secretory cell that supports Lgr5(C) stem cells in mice. Gastroenterology 142, 1195-1205.e6 (2012).
62. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007).
63. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
64. Hu, Y. &Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
65. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).